

Once-weekly **REZZAYO**[®] (rezafungin for injection) may simplify your invasive candidiasis treatment



You've been prescribed **REZZAYO**[®] by your healthcare provider. Unlike daily antifungal treatments, **REZZAYO**[®] is a *once-weekly* antifungal treatment given through intravenous (IV) infusion for 1 hour.

Once-weekly
REZZAYO[™] 
(rezafungin for injection)

What is **REZZAYO[®] (rezafungin for injection)?**

REZZAYO[®] is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called *Candida*. It is given once-weekly through the vein (intravenous or IV).

REZZAYO[®] is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of **REZZAYO**[®] was based on limited clinical safety and efficacy data. **REZZAYO**[®] was not studied in patients with *Candida* infections in the heart, bone, or brain.

When should I NOT take **REZZAYO[®]?**

You should not take **REZZAYO**[®] if you are allergic to rezafungin or other antifungal drugs called echinocandins.

Please see additional Important Safety Information throughout and full [Prescribing Information](https://www.rezzayo.com) at [REZZAYO.com](https://www.rezzayo.com).

What to expect with **REZZAYO**[®]

In clinical trials with over 200 adults with candidemia and invasive candidiasis, *once-weekly REZZAYO*[®] was shown to be as effective as a daily infusion of caspofungin, another echinocandin antifungal.

As you can see in the chart below, with *REZZAYO*[®], an infusion is needed only once a week—rather than daily—making it easier to fit into your schedule.



*Unlike daily IV antifungal treatment, *REZZAYO*[®] does not require a central IV line (often referred to as a PICC line), which is a long, thin tube that must be inserted into the arm for an extended period of time in order to administer the drug.



REZZAYO[®] is delivered to your bloodstream through a needle in a vein. It is slowly infused over 1 hour.



Your infusion with *REZZAYO*[®] can be given to you at a hospital, at an infusion center, or even at home by a nurse and **can be taken safely with other commonly prescribed medications.**



Unlike daily IV antifungal treatment, *REZZAYO*[®] **does not require a central IV line (often referred to as a PICC line)**, which is a long, thin tube that must be inserted into the arm for an extended period of time in order to administer the drug.



The most common side effects of *REZZAYO*[®] are fever, diarrhea, anemia, vomiting, nausea, stomach pain, constipation, and low levels of potassium, magnesium, or phosphate in the blood.

Talk to your healthcare provider about the best place for you to receive your treatment. Please see full [Prescribing Information](#) for additional safety information.

IMPORTANT SAFETY INFORMATION FOR PATIENTS (continued)

What should I discuss with my healthcare provider before taking *REZZAYO*[®]?

Before starting *REZZAYO*[®], tell your healthcare provider about all of the medications you are taking and all of your medical conditions, including if you are allergic to rezafungin or other antifungal drugs called echinocandins.

Please see additional Important Safety Information on throughout and full [Prescribing Information](#) at [REZZAYO.com](#).



Financial assistance programs may be available

Once-weekly
REZZAYO[™] >>>
(rezafungin for injection)

Copay savings program

- Copay support for eligible patients with private commercial insurance[†]
 - » **Up to \$800 for 400-mg loading dose**
 - » **Up to \$400 per 200-mg vial**
 - » **No out-of-pocket minimum**
- Patient must be 18 years of age or older and a US resident
- Patient must be treated in an outpatient setting of care
- There is no income requirement to qualify for the copay savings program

A **patient assistance program (PAP)** may be available for uninsured patients demonstrating financial need if they meet household income requirements and reside in the United States.



Ask your healthcare provider for more information

[†]A patient will not qualify if they have a prescription drug benefit through a government program (ie, Medicaid, Medicare, Medicare Part D, Medigap, CHAMPUS, DOD, VA, TRICARE, or any state patient or pharmaceutical assistance program). As a condition for receiving copays or coinsurance, both healthcare professionals and patients are required to inform patients' insurance companies and third-party payers of any copays or coinsurance benefits paid by this program. Void where prohibited by law, taxed, or restricted. Additional terms and conditions may apply. Patients enrolled in the REZZAYO[®] Patient Assistance Program are not eligible. Melinta Therapeutics, LLC may determine eligibility, monitor participation, and modify or discontinue any aspect of this program at any time.

The importance of following and completing your treatment with REZZAYO[®]

Remember, invasive candidiasis is a serious condition, and it is important to take your prescribed medication as directed.

Work with your healthcare team to determine a schedule for your infusions that will work best for you. Contact your healthcare team for assistance if you have any questions or concerns about your REZZAYO[®] treatment or treatment schedule.

IMPORTANT SAFETY INFORMATION FOR PATIENTS (continued)

What is the most important information I need to know about taking REZZAYO[®]?

- You may experience certain reactions when you are receiving REZZAYO[®] in the IV, including flushing, warm sensations, hives, nausea, or tightness in the chest. If these reactions occur, tell your healthcare provider. They may slow or stop the IV.
- Photosensitivity: REZZAYO[®] may cause you to be more sensitive to sunlight. While taking REZZAYO[®], protect yourself from sun exposure and other sources of ultra-violet (UV) radiation.
- In the clinical trials for REZZAYO[®], some patients had abnormal liver tests. Your healthcare provider will monitor you if you develop abnormal liver tests and decide whether you should keep taking REZZAYO[®].

Please see additional Important Safety Information throughout and full [Prescribing Information](#) at [REZZAYO.com](#).

What is candidemia/ invasive candidiasis?

Candidemia/invasive candidiasis (IC) is an infection in your blood. It happens when a tiny yeast (a type of fungus) called *Candida* grows too much. This yeast normally lives on your skin and in places like your mouth, throat, and gut. But sometimes it can get into your bloodstream and go to different parts of your body.

When this occurs, it's called invasive candidiasis. If left untreated, it can spread to your organs and may cause death. This condition is often treated by a class of medications called echinocandins (ek-ih-noh-KAN-dinz). These can include caspofungin, micafungin, and anidulafungin, which are IV treatments given daily, often via a central IV line or a PICC.

Talk to your healthcare team if you have questions about once-weekly REZZAYO®.

Once-weekly
REZZAYO™ >>>
(rezafungin for injection)



IMPORTANT SAFETY INFORMATION FOR PATIENTS

What is REZZAYO® (rezafungin for injection)?

REZZAYO® is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called *Candida*. It is given once-weekly through the vein (intravenous or IV).

REZZAYO® is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of REZZAYO® was based on limited clinical safety and efficacy data. REZZAYO® was not studied in patients with *Candida* infections in the heart, bone, or brain.

What should I discuss with my healthcare provider before taking REZZAYO®?

Before starting REZZAYO®, tell your healthcare provider about all of the medications you are taking and all of your medical conditions, including if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What is the most important information I need to know about taking REZZAYO®?

- You may experience certain reactions when you are receiving REZZAYO® in the IV, including flushing, warm sensations, hives, nausea, or tightness in the chest. If these reactions occur, tell your healthcare provider. They may slow or stop the IV.
- Photosensitivity: REZZAYO® may cause you to be more sensitive to sunlight. While taking REZZAYO®, protect yourself from sun exposure and other sources of ultra-violet (UV) radiation.
- In the clinical trials for REZZAYO®, some patients had abnormal liver tests. Your healthcare provider will monitor you if you develop abnormal liver tests and decide whether you should keep taking REZZAYO®.

When should I NOT take REZZAYO®?

You should not take REZZAYO® if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What are some of the most common side effects of REZZAYO®?

Most common side effects of REZZAYO® are fever, diarrhea, anemia, vomiting, nausea, stomach pain, constipation, and low levels of potassium, magnesium, or phosphate in the blood.

Please see full [Prescribing Information](#) for additional safety information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088 (1-800-322-1088).



The risk information provided here is not comprehensive. The information in this brochure should not take the place of talking with your doctor or healthcare professional. If you have any questions about your condition, or if you would like more information about your medicine, talk to your doctor. Only you and your healthcare professional can decide which medicine is right for you.

To report an adverse event, other safety-related information, or product complaints for REZZAYO®, please contact Medical Information.
[1-844-MED-MLNT \(1-844-633-6568\)](tel:1-844-MED-MLNT)
medinfo@melinta.com

©2024 Melinta Therapeutics, LLC
All Rights Reserved. 03/2024
PP-REZ-US-0279